title: Duration of preventive antibiotic administration for open extremity fractures.
abstract: The necessary duration of antibiotic administration after open fracture has not been established. In a double-blind prospective trial we randomized 248 patients with open fractures to receive one or five days of cefonicid sodium therapy or five days of cefamandole nafate therapy as part of the initial treatment. Rates of fracture-associated infections in the three groups were ten (13%) of 79, ten (12%) of 85, and 11 (13%) of 84, respectively. The 95% confidence limit for the difference in infection rates between the one-day group and the combined five-day groups was 0% to 8.3%. The actual difference was 0.2%. A brief course of antibiotic administration is not inferior to a prolonged course of antibiotics for prevention of postoperative fracture-site infections.
authors.affiliation: Department of Surgery, University of Washington, Seattle 98104.
authors.forename: E P
authors.initials: EP
authors.lastname: Dellinger
authors.forename: E S
authors.initials: ES
authors.lastname: Caplan
authors.forename: L D
authors.initials: LD
authors.lastname: Weaver
authors.forename: M J
authors.initials: MJ
authors.lastname: Wertz
authors.forename: B M
authors.initials: BM
authors.lastname: Droppert
authors.forename: N
authors.initials: N
authors.lastname: Hoyt
authors.forename: R
authors.initials: R
authors.lastname: Brumback
authors.forename: A
authors.initials: A
authors.lastname: Burgess
authors.forename: A
authors.initials: A
authors.lastname: Poka
authors.forename: S K
authors.initials: SK
authors.lastname: Benirschke
mesh_terms: D000328:Adult; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control*; D002435:Cefamandole / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D015790:Cefonicid; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005121:Extremities / Q000293:injuries*; D005260:Female; D005597:Fractures, Open / Q000150:complications* / Q000628:therapy; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011897:Random Allocation
chemical_list: D002435:Cefamandole; D015790:Cefonicid